Want to see LFWD full AI Analyst Report?
LFWD Stock Chart & Stats
$7.49
-$0.16(-2.30%)
At close: 4:00 PM EDT
$7.49
-$0.16(-2.30%)
Day’s Range― - ―
52-Week Range$4.14 - $10.21
Previous CloseN/A
Volume3.69K
Average Volume (3M)4.82K
Market Cap
$18.69M
Enterprise Value$23.04
Total Cash (Recent Filing)$9.45M
Total Debt (Recent Filing)$11.07M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Nov 17, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.82
Shares Outstanding2,832,016
10 Day Avg. Volume4,317
30 Day Avg. Volume4,815
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)9.55
Price to Sales (P/S)3.64
P/FCF Ratio-4.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside33.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.65
Revenue Forecast (FY)$28.78M
Bulls Say, Bears Say
Bulls Say
Revenue ScaleLifeward has materially expanded revenue over several years, demonstrating growing commercial adoption of its mobility solutions. This broader revenue base can support operating leverage and greater market reach, although profitability still needs to improve for growth to create durable shareholder value.
Commercial ReachA sizeable international distribution footprint, an installed base exceeding 7,000 units, and meaningful payer access provide established channels for commercialization. These assets can reduce market-entry friction and support repeat sales, accessories, and service opportunities as reimbursement develops.
Product PipelineLifeward is pursuing multiple rehabilitation and mobility products rather than relying solely on one exoskeleton system. A broader portfolio could expand the addressable customer base, create cross-selling opportunities, and strengthen the company’s position in a fragmented rehabilitation technology market.
Bears Say
Severe UnprofitabilityExtremely negative operating and net margins show that the current cost structure is not scaling with revenue. Unless Lifeward substantially improves gross profit contribution or reduces operating expenses, continued sales growth may not translate into earnings, limiting financial resilience over the next several quarters.
Persistent Cash BurnLifeward is not yet self-funding: operating and free cash flow remain materially negative despite some improvement from 2024. Persistent burn can consume available liquidity, constrain investment in the product pipeline, and force additional financing before the business reaches sustainable scale.
Financing And Governance RiskConvertible notes and warrants provide needed funding but add 8% interest expense, secured obligations, and potential equity dilution. At the same time, CEO and CFO transitions create an execution and governance burden, making consistent strategy and financial oversight more important during commercialization.
Lifeward News
LFWD FAQ
What was Lifeward’s price range in the past 12 months?
Lifeward lowest stock price was $4.14 and its highest was $10.21 in the past 12 months.
What is Lifeward’s market cap?
Lifeward’s market cap is $18.69M.
When is Lifeward’s upcoming earnings report date?
Lifeward’s upcoming earnings report date is Nov 17, 2026 which is in 46 days.
How were Lifeward’s earnings last quarter?
Lifeward released its earnings results on Aug 14, 2026. The company reported -$1.46 earnings per share for the quarter, missing the consensus estimate of -$1.386 by -$0.074.
Is Lifeward overvalued?
According to Wall Street analysts Lifeward’s price is currently Undervalued.
Does Lifeward pay dividends?
Lifeward does not currently pay dividends.
What is Lifeward’s EPS estimate?
Lifeward’s EPS estimate is -0.79.
How many shares outstanding does Lifeward have?
Lifeward has 2,832,016 shares outstanding.
What happened to Lifeward’s price movement after its last earnings report?
Lifeward reported an EPS of -$1.46 in its last earnings report, missing expectations of -$1.386. Following the earnings report the stock price went down -5.636%.
Which hedge fund is a major shareholder of Lifeward?
Currently, no hedge funds are holding shares in LFWD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lifeward
Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living with spinal cord injuries (SCI), granting them the ability to stand, walk, pivot, and navigate staircases by providing assistive hip and knee motion. Key offerings from the company include the ReWalk Exo-Suit and the ReWalk Personal 6.0. Founded by Amit Goffer on June 20, 2001, the enterprise maintains its corporate headquarters in Marlborough, Massachusetts.
LFWD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced mix of strategic, financial and operational positives (acquisitions, stronger cash position, ReWalk growth, cost reductions and reduced cash burn) offset by meaningful near-term operational headwinds (22% revenue decline, 800 bps gross margin compression, increased GAAP loss and manufacturing/supply chain disruptions). Management expects to resolve AlterG timing issues across Q2–Q3, sees a path to profitability and holds revenue expectation similar to prior year but retains execution risk during the transition.View all LFWD earnings summariesLFWD Stock 12 Month Forecast
Average Price Target
$10.00
▲(33.51% Upside)
Technical Analysis
Ownership Overview
15.84% Insiders
<0.01% Mutual Funds
― Other Institutional Investors
84.12% Public Companies and
Individual Investors